The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-30
SponsorStanford University

About this trial

Patients who tear their ACL are at high risk for developing arthritis (post-traumatic osteoarthritis-PTOA) just 10 years later. Joint bleeding and inflammation contribute to deterioration of joint health. This study will determine whether treatment with Tranexamic Acid (TXA), an FDA approved medication that reduces bleeding right after ACL injury and reconstructive surgery reduces inflammation and improves joint health as a new strategy to prevent or delay the onset of PTOA.

Eligibility criteria

Qualifiers

age 18-30 years

within 4 days of unilateral ACL injury

presence of effusion/hemarthrosis.

Disqualifiers

inflammatory arthritis, radiographic osteoarthritis (K-L Grade 2 or higher), gout/ pseudogout

systemic or acute illness requiring medications

concomitant knee injury aside from meniscus tear and MCL tear not requiring surgery

prior surgery to either knee

Trial design

Treatments tested in this trial

  • Tranexamic Acid
  • Placebos

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Stanford University

Lead sponsor

United States Department of Defense

Collaborator